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Rheumatoid arthritis (RA) is the prototype of a group of
disorders characterized by chronic inflammatory reaction of
the joints. The persistent inflammation results from the
coordinated infiltration of the synovial tissue by distinct
cellularpopulationswhichareactivatedandreleaseacomplex
network of cytokines, chemokines, and growth factors.
Progress in the understanding of the pathophysiology of RA
and other forms of inflammatory arthritis has led to the
concept of targeting cellular activation or cytokines in an
attempt to better control the inflammatory process. In this
sense, biological therapies blocking TNFα, IL-1 or IL-6, or
controlling costimulatory pathways or alternatively B cells
have emerged. These new therapies are currently available in
the treatment of patients with RA, contributing to a better
management of the disease.
The various mediators driving inflammation in RA and
different forms of arthritis do so through the activation of
conserved intracellular signaling proteins and pathways
such as NF-κB, JAK/STAT or PI3 kinases which can be
additional targets for a therapeutic intervention (Morel and
Berenbaum 2004). Indeed, extracellular stimuli mediate
their message to the nucleus through these signaling
pathways and by means of transcriptional factors which
interact with the promoter region of responder genes. Gene
transcription may be modulated by epigenetic modifications
which involved different reactions such as methylation of
DNA and phosphorylation, sumoylation, ubiquitination, or
acetylation of histone proteins (Huber et al. 2007a). All
these histone reactions induce changes in the chromatin
conformation and regulate transcriptional factor access to
gene encoding regions of DNA (Karouzakis et al. 2009;
Rosato and Grant 2004; Blanchard and Chipoy 2005;
Glaser 2007; Halili et al. 2009; Grabiec et al. 2008).
Acetylation of histone proteins is regulated by the
opposite action of histone acetyl transferase (HAT) and
histone deacetylase (HDAC) enzymes. It is accepted that
HAT activity promotes chromatin relaxation, favors the
fixation of transcriptional factors and consequently
transcriptional activation (including the transcription of
inflammatory genes) while HDAC reverses this process,
inducing chromatin condensation and preventing tran-
scriptional factor access to gene promoters (Blanchard
and Chipoy 2005;G l a s e r2007; Halili et al. 2009;G r a b i e c
et al. 2008). However, it has also been demonstrated that
HDAC enzymes (and HAT enzymes as well) also interact
with non-histone proteins including proteins for signaling
pathways or transcriptional factors. Therefore, HDAC may
have histone-independent effects in gene regulation
(Grabiec et al. 2008).
Since HDAC activity may prevent the recruitment of
transcriptional factors and silent gene transcription, includ-
ing tumor repressor genes, HDAC inhibitors (HDACi) have
been developed in the treatment of cancer (Lane and
Chabner 2009). In fact, epigenetic modifications are
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been demonstrated that HDACi partially control some
epigenetic alterations associated with tumorigenesis. Hyper-
acetylation of histones by HDACi leads to the expression of
repressed genes that inhibits cell proliferation and induces
cell differentiation or apoptosis in tumor cells. Various
HDACi are currently being tested in different forms of
cancer, and vorinostat (SAHA, a pan-HDACi), for instance,
has recently been approved for the treatment of cutaneous T
cell lymphoma (Duvic et al. 2007). Four classes of HDAC
(HDACI, II, III, and IV) have been described and they are
grouped based on their structural homology with HDAC
found in yeast (Rosato and Grant 2004; Blanchard and
Chipoy 2005; Glaser 2007; Halili et al. 2009). Histone
deacetylase inhibitors are synthetic or naturally derived and
a wide range of products is currently being tested in cancer
or various inflammatory or degenerative disorders (MA et
al. 2009). These inhibitors can be structurally grouped into
four classes, including hydroxamate, cyclic peptide, ali-
phatic acids, and benzamide. They are pan or selective
inhibitors of HDAC activities. Many HDACi used up to
now are active against Class I and Class II enzyme
activities (trichostatin A and vorinostat for instance) while
certain compounds are selective for HDAC Class (FK 228
inhibits HDAC1 and 2).
Besides their anti-neoplastic properties, it has been
reported that HDACi may be used to treat inflammatory
diseases via inhibition of cell proliferation and reduction of
inflammatory cytokine production. This was observed with
trichostatin A (TSA) and butyrate in ulcerative colitis,
which inhibited IL-8 production (Yin et al. 2001). Thus,
HDACi were investigated as potent anti-inflammatory
drugs in different inflammatory conditions including arthritis
(Segain et al. 2000).
Studies in animal models of arthritis have given the
rationale for testing HDACi in human conditions and
particularly in RA:
– The first report of HDACi in the treatment of arthritis
was reported by Chung et al. (2003). Topical applica-
tion of phenylbutyrate or TSA on rat paws prior to the
induction of adjuvant-induced arthritis reduced joint
swelling. Histological examination of the treated joints
showed that synovial infiltration, synovial hyperplasia,
and bone erosion were reduced. In addition, TNFα
expression in the synovium was reduced while there
was an accumulation of acetylated histones and an
increased expression of the cell cycle inhibitors p16
lnk4
and p21
Waf1.
– Another HDACi, FK228, was tested in the same model
of arthritis. When it was given systemically prior to the
induction of arthritis, FK228 may prevent joint inflam-
mation and the development of joint erosions. When it
was given after the onset of arthritis, it also reduced
paw swelling and bone erosions. In addition, FK228
suppressed osteoclast function by the expression of
IFNβ, an osteoclast inhibitory protein (Nakamura et al.
2005).
– FK228 was also tested in the autoantibody-mediated
arthritis in mice. A single systemic injection of this
compound inhibited joint swelling, synovial inflamma-
tion and cartilage and bone destruction. Histone
proteins were hyperacetylated in the synovial cells
and TNFα and IL-1β expression was reduced. Again,
the expression of p16
lnk4 was induced and p21
waf1 was
up-regulated (Nishida et al. 2004).
– Collagen-induced arthritis is another animal model of
RA. The effects of 2 HDACi, vorinostat (SAHA), and
MS-275 were evaluated in murine and rat collagen-
induced arthritis. A subcutaneous injection of SAHA
attenuated joint inflammation and reduced bone
erosions. By contrast, the administration of MS-275
was associated with complete resolution of arthritis.
MS-275 was effective both in a prophylactic and in a
therapeutic intervention. In addition, serum IL-6 and
IL-1β levels were reduced with MS-275. A histolog-
ical examination confirmed the anti-rheumatic activity
of MS-275, showing no synovial hyperplasia, pannus
formation, or cartilage or bone destruction (Lin et al.
2007).
– Trichostatin A given subcutaneously in the mouse
model of collagen-induced arthritis also displayed
anti-inflammatory activity. It improved arthritis and
synovial inflammation, and limited bone destruction. In
addition, positive chondrocytes for metalloproteinase
MMP-3 and MMP-13 were reduced under TSA (Nasu
et al. 2008).
– In the mouse model of collagen-induced arthritis,
the intra-peritoneal administration of valproic acid
decreased arthritis incidence and severity. This treatment
was associated with an increase in the number and
function of CD25+ Foxp3+ regulatory T cells (Saouaf et
al. 2009).
All these data demonstrated the anti-inflammatory
properties of different HDACi in the prevention and
treatment of various forms of animal models of arthritis.
These compounds were able to reduce inflammation in the
joints, down-regulate the production of pro-inflammatory
cytokines and control cartilage and bone erosions.
Conversely, only a limited number of studies have
examined the role and influence of HAT and HDAC
activities in patients with RA:
– Huber et al. examined the synovial expression of HAT
and HDAC in a small number of patients with RA,
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ity was reduced in synovial tissue samples from
patients with RA compared to the other groups, while
there was no difference in the HAT activity between the
three groups. This resultwas interpreted by the authors as
a situation favoring transcription of pro-inflammatory
genes (Huber et al. 2007b).
– By contrast, Horiuchi et al. found that synovial
fibroblasts from patients with RA expressed more
HDAC1 mRNA than the same cells from patients with
OA. The blockade of HDAC1 and HDAC2 activities
using small interfering RNA resulted in a decreased
cell proliferation and an increased apoptosis in RA
synovial fibroblasts (Horiuchi et al. 2009).
– It has also been demonstrated that Trichostatin A
induced the cell death of RA synovial fibroblasts in a
synergistic and dose-dependent manner when given
with a TNF related apoptosis-inducing ligand (TRAIL;
Jüngel et al. 2006).
Together with the data from animal models of arthritis,
all these results strongly support the potential involvement
of HDAC and HAT activities in the regulation of cellular
activation and the production of pro-inflammatory cyto-
kines in animal models of arthritis and also in patients with
RA. The anti-inflammatory properties of HDACi may be
explained in part by the regulation in the HAT/HDAC
balance but also by interfering with non-histone proteins,
including transcriptional factors such as p65 NF-κB, IκB,
FoxO and JAK/STAT (Ashburner et al. 2001; Imre et al.
2006; Viatour et al. 2003; Mahlknecht et al. 2004). The
final result is that HDACi may have an impact on several
cellular populations: they can limit T lymphocyte activation
and stimulate T regulatory cells (Brogdon et al. 2007; Wang
et al. 2009); they can inhibit TNFα, IL-1β, IL-12, and
IFNγproductionbymonocytesandthereleaseofchemokines
andcytokinesbymacrophagesanddendriticcells(Leonietal.
2002;S ue ta l .2008); they can inhibit the angiogenesis
process (Wang et al. 2009); they inhibit osteoclast function
as well as metalloprotease and aggrecan-degrading enzyme
production by chondrocytes (Young et al. 2005; Chabane et
al. 2008). Because of all these mechanisms, the new HDACi
class drug seems very attractive for the treatment of RA and
other forms of arthritis (Choo et al. 2008).
However, for a better understanding of the role of the
HAT/HDAC enzyme activities in RA, the following
questions must be considered:
– Although the consequences of acetylation and deacetyla-
tion on histone proteins are relatively well understood
(with some paradoxical findings), the interactions
between HDAC and HAT with non-histone proteins
remain only partially characterized. In particular, the exact
influence of HDAC enzymes on the different transcrip-
tional factors that play a role in the inflammatory response
of RA must be evaluated. We have some responses, but
more studies on these interactions are needed.
– We have limited and partially contradictory data on the
expression of HAT and HDAC in patients with RA
(Huber et al. 2007b; Horiuchi et al. 2009). In particular,
we do not know about the distribution and expression
of the distinct HDAC activities in the different cellular
populations that infiltrate the RA synovium. Determin-
ing which HDAC is important for the activation and
survival of these cell populations will indicate whether
a selective HDACi or a pan-HDACi would be useful in
the therapeutic management of patients. This question
is relevant in order to identify the right therapeutic
target and to define the adequate therapeutic tool.
– Wedonotknowifthecurrenttreatmentsthatweareusing
in RA (both traditional disease modifying anti-rheumatic
drugs and biologics) have an influence on HAT and
HDAC activities.
Thus,allthesestudieshaveprovidedtherationalefortheuse
of this new and promising therapeutic drug class for arthritis,
but further analyses are required to better understand the
contribution of HATand HDAC to the synovial inflammation.
It seems particularly crucial to clarify the anti-inflammatory
mechanisms of these drugs, which are certainly more complex
than the single acetylation/deacetylation of histone proteins. In
particular, an imbalance in theratio acetylation/deacetylationof
both histone and non-histone proteins could lead to a sustained
inflammatory state leading to arthritis. Thus, a better under-
standing of the molecular mechanisms involved in the RA
pathogenesis could lead to the development of new therapeutic
approaches, allowing for further developments in clinical trials
in the very near future (Kwon et al. 2002).
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